Phase II study of FOLFIRI with low-dose irinotecan plus ramucirumab as second-line treatment in Japanese patients with metastatic colorectal cancer (study rindo)
FOLFIRI with low-dose irinotecan plus RAM is a feasible second-line treatment in Japanese patients with mCRC.
Authors
- Yasuhiro Kodera (ORCID: https://orcid.org/0000-0002-6173-7474)
- Mitsuro Kanda (ORCID: https://orcid.org/0000-0001-5464-3819)
- Kenta Murotani (ORCID: https://orcid.org/0000-0003-0623-9365)
- Goro Nakayama
- Norifumi Hattori (ORCID: https://orcid.org/0000-0002-1433-7208)
- Masayuki Tsutsuyama (ORCID: https://orcid.org/0000-0002-2157-0796)
- Chie Tanaka (ORCID: https://orcid.org/0000-0002-0829-7342)
- Takayoshi Kishida
- Kazuhiro Ezaka
- Masahiko Ando (ORCID: https://orcid.org/0000-0003-2891-5424)
- Masashi Hattori (ORCID: https://orcid.org/0000-0002-4021-1051)
- Takeshi Ito (ORCID: https://orcid.org/0000-0003-2236-9282)
- Mitsuru Sakai
- Shinichi Umeda
- Shigeomi Takeda
Institutions
- Kurume University (JP)
- Nagoya University Hospital (JP)
- Ichinomiya Municipal City Hospital (JP)
- Toyohashi Municipal Hospital (JP)
- Komaki City Hospital (JP)
- Yokkaichi Municipal Hospital (JP)
- Nagoya Medical Center (JP)
- Tosei General Hospital (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1093/jjco/hyaf198
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Japan Society of Clinical Oncology
- Eli Lilly Japan